Codexis, Inc. discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering protein catalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorIndustrial Products
Phone650-421-8100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50.02 million
Profitability
Miscellaneous
Employees116
OptionableOptionable
Codexis (NASDAQ:CDXS) Frequently Asked Questions
What is Codexis' stock symbol?
Codexis trades on the NASDAQ under the ticker symbol "CDXS."
How were Codexis' earnings last quarter?
Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03. The biotechnology company earned $16.95 million during the quarter, compared to analysts' expectations of $14.63 million. Codexis had a negative return on equity of 25.72% and a negative net margin of 14.26%. View Codexis' Earnings History.
When is Codexis' next earnings date?
What guidance has Codexis issued on next quarter's earnings?
Codexis updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $60-62 million.
What price target have analysts set for CDXS?
6 equities research analysts have issued twelve-month price objectives for Codexis' stock. Their predictions range from $16.50 to $25.00. On average, they expect Codexis' share price to reach $19.75 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View Analyst Price Targets for Codexis.
What is the consensus analysts' recommendation for Codexis?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Codexis.
What are Wall Street analysts saying about Codexis stock?
Here are some recent quotes from research analysts about Codexis stock:
- 1. According to Zacks Investment Research, "Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. " (1/17/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of CDXS and our 12-month price target of $16.50 per share. We derive our price target based on the average of three valuation methods: 1) price-sales multiple analysis applying a 3x multiple to our 2025 risk-adjusted revenue estimate discounted at 12%; 2) price-earnings multiple analysis applying a 23x multiple to our 2025 estimated earnings discounted at 12%; and 3) discounted free cash flow analysis assuming a 12% discount rate and a 2% terminal growth rate." (1/14/2019)
Has Codexis been receiving favorable news coverage?
News coverage about CDXS stock has been trending negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Codexis earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Codexis' key competitors?
Some companies that are related to Codexis include Sensient Technologies (SXT), Renewable Energy Group (REGI), Westlake Chemical Partners (WLKP), FutureFuel (FF), Green Plains (GPRE), Green Plains Partners (GPP), REX American Resources (REX), Sino United Worldwide Consolidated (SUIC), Amyris (AMRS), Solarwindow Technologies (WNDW), CTD (CTDH), Pacific Ethanol (PEIX), Tantech (TANH), Wave Sync (WAYS) and Gevo (GEVO).
Who are Codexis' key executives?
Codexis' management team includes the folowing people:
- Mr. John J. Nicols, Pres, CEO & Director (Age 55)
- Mr. Gordon T. B. Sangster, Sr. VP & CFO (Age 66)
- Dr. James J. Lalonde, Sr. VP of R&D (Age 58)
- Mr. Achilles Antonio Clement, Director of Latin America
- Ms. Shawn Clairmont, Sr. Director of Molecular Diagnostics
Who are Codexis' major shareholders?
Codexis' stock is owned by many different of retail and institutional investors. Top institutional investors include Pratt Collard Advisory Partners LLC (0.07%) and Boston Advisors LLC (0.04%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Institutional Ownership Trends for Codexis.
Which major investors are selling Codexis stock?
CDXS stock was sold by a variety of institutional investors in the last quarter, including Pratt Collard Advisory Partners LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Michael D Aldridge, Pam P Cheng, Patrick Y Yang and Thomas R Baruch. View Insider Buying and Selling for Codexis.
Which major investors are buying Codexis stock?
How do I buy shares of Codexis?
Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Codexis' stock price today?
One share of CDXS stock can currently be purchased for approximately $17.39.
How big of a company is Codexis?
Codexis has a market capitalization of $862.64 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.
What is Codexis' official website?
How can I contact Codexis?
Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]
MarketBeat Community Rating for Codexis (NASDAQ CDXS)
MarketBeat's community ratings are surveys of what our community members think about Codexis and other stocks. Vote "Outperform" if you believe CDXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
